Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 10/20 | 0.49 |
| ▸ | TACR1 | P25103 | 8/20 | 0.49 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.49 |
| ▸ | RHOA | P61586 | 7/20 | 0.46 |
| ▸ | RHOC | P08134 | 5/20 | 0.46 |
| ▸ | TACR3 | P29371 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444073 | 1.00 | TACR2 (0.49) | TACR2TACR1TAC3RHOARHOC | |
| SCHEMBL6442216 | 0.93 | RHOA (0.44) | TACR2TACR1TAC3RHOARHOC | |
| SCHEMBL6442215 | 0.93 | RHOA (0.44) | TACR2TACR1TAC3RHOARHOC | |
| SCHEMBL5918142 | 0.90 | RHOA (0.54) | TACR1RHOARHOC | |
| SCHEMBL5918143 | 0.90 | RHOA (0.54) | TACR1RHOARHOC | |
| SCHEMBL6440354 | 0.89 | TACR2 (0.49) | TACR2TACR1TAC3RHOARHOC | |
| SCHEMBL6440351 | 0.89 | TACR2 (0.49) | TACR2TACR1TAC3RHOARHOC | |
| SCHEMBL7251202 | 0.88 | TACR1 (0.49) | TACR2TACR1TAC3RHOARHOC | |
| SCHEMBL6443375 | 0.88 | TACR1 (0.49) | TACR2TACR1TAC3RHOARHOC | |
| SCHEMBL5918094 | 0.87 | TACR1 (0.45) | TACR2TACR1RHOARHOCTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360184-B1 | PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6642226-B2 | Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | TACR1, OPRK1, TACR2 | TACR2 3/4885TACR1 1/4885TAC3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.